Skip to main content
. 2022 Aug;33(8):1569–1580. doi: 10.1681/ASN.2022020207

Figure 4.

Figure 4.

Percent change from baseline in UACR after 4 weeks of treatment with dapagliflozin, eplerenone, and dapagliflozin-eplerenone in patient subgroups defined by baseline characteristics. The effects on UACR are presented in prespecified subgroups. The solid dot represents the estimate of the treatment effect in subgroups; the horizontal line the corresponding 95% confidence interval.